Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorRomán Alonso, Macarena
dc.contributor.authorLuque García, Antonio
dc.contributor.authorFajardo, Carlos Alberto
dc.contributor.authorGros Vidal, Alena
dc.contributor.authorArribas López, Joaquin Vicente
dc.contributor.authorArenas Lahuerta, Enrique Javier
dc.contributor.authorMartínez-Sabadell, Alex
dc.contributor.authorRius Ruiz, Irene
dc.contributor.authorEscorihuela Baez, Marta
dc.date.accessioned2022-01-25T12:14:18Z
dc.date.available2022-01-25T12:14:18Z
dc.date.issued2021-02-23
dc.identifier.citationArenas EJ, Martínez-Sabadell A, Rius Ruiz I, Román Alonso M, Escorihuela M, Luque A, et al. Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Nat Commun. 2021 Feb 23;12:1237.
dc.identifier.issn2041-1723
dc.identifier.urihttps://hdl.handle.net/11351/6893
dc.descriptionImmunoteràpia del càncer; Resistència terapèutica del càncer
dc.language.isoeng
dc.publisherNature Research
dc.relation.ispartofseriesNature Communications;12
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCàncer - Immunoteràpia
dc.subjectResistència als medicaments
dc.subject.meshNeoplasms
dc.subject.mesh/immunology
dc.subject.meshDrug Resistance, Neoplasm
dc.titleAcquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s41467-021-21445-4
dc.subject.decsneoplasias
dc.subject.decs/inmunología
dc.subject.decsresistencia a los antineoplásicos
dc.relation.publishversionhttps://doi.org/10.1038/s41467-021-21445-4
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Arenas EJ, Rius Ruiz I] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid 28029, Spain. [Martínez-Sabadell A, Román Alonso M, Escorihuela M, Luque A] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Fajardo CA, Gros A] Tumor Immunology & Immunotherapy Group, VHIO, Barcelona, Spain. [Arribas J] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid 28029, Spain. Tumor Immunology & Immunotherapy Group, VHIO, Barcelona, Spain. Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona 08003, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, Spain
dc.identifier.pmid33623012
dc.identifier.wos000623781900011
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail
Thumbnail
Thumbnail
Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple